Filtered By:
Condition: Aortic Stenosis
This page shows you your search results in order of relevance. This is page number 5.
Order by Relevance | Date
Total 1228 results found since Jan 2013.
Carotid Duplex Poorly Predicts Stroke Risk During Transcatheter Aortic Valve Replacement
Patients undergoing surgical aortic valve replacement, in isolation or with concomitant coronary artery bypass grafting, have historically been screened for carotid artery disease prior to surgery. Over the past decade, transcatheter aortic valve replacement (TAVR) has incrementally become the predominant technique for the treatment of severe aortic stenosis. The relationship between internal carotid artery stenosis (ICAS) and risk of periprocedural stroke in the TAVR population is uncertain. We sought to evaluate our institution's outcomes with the TAVR procedure and the association with preoperative carotid duplex scan (CDS) results.
Source: Annals of Vascular Surgery - January 4, 2022 Category: Surgery Authors: Cameron St. Hilaire, Jaclyn DeRieux, Michael Shenoda, Kevin Casey Tags: Clinical Research Source Type: research
Implementation of a CT-derived correction factor to refine the measurement of aortic valve area and stroke volume using Doppler echocardiography improves grading of severity and prediction of prognosis in patients with severe aortic stenosis
Aims: To assess rates of reclassification of severity and associated 5-year survival in patients with severe aortic stenosis (AS) and preserved left ventricular ejection fraction (LVEF) after application of a CT-derived correction factor (CF) to refine the measurement of aortic valve area (AVA) and stroke volume index (SVi) using Doppler echocardiography.Methods and Results: We enrolled 1450 patients with severe AS and preserved LVEF from a French registry. Multiplication of echocardiographic LV outflow tract diameter by a CT-derived CF of 1.13 to calculate the AVA and SVi using the continuity equation resulted in reclassi...
Source: International Journal of Cardiology - June 15, 2022 Category: Cardiology Authors: Attila Kardos, Dan Rusinaru, Sylvestre Mar échaux, Ebraham Alskaf, Bernard Prendergast, Christophe Tribouilloy Source Type: research
Cerebral Embolic Protection Does Not Prevent Stroke in TAVR
FRIDAY, Sept. 30, 2022 -- The use of cerebral embolic protection (CEP) does not have a significant impact on the incidence of periprocedural stroke among patients with aortic stenosis undergoing transfemoral transcatheter aortic-valve replacement...
Source: Drugs.com - Pharma News - September 30, 2022 Category: Pharmaceuticals Source Type: news
Measurement of stroke volume with echocardiography compared to gold standard cardiac magnetic resonance imaging An observational study
The assessment of Doppler-derived left ventricular outflow tract (LVOT) stroke volume (SV) is fundamental in outpatient, perioperative and critical care echocardiography.1 Calculation of SV allows assessment of the severity of aortic stenosis (AS) and evaluation of the haemodynamic state during undifferentiated hypotension.2 The use of focused transthoracic echocardiography (TTE) has appeal in a critical care environment, where after a single measurement of the LVOT area, pulsed wave Doppler velocity time integral (VTI) in the LVOT is used to calculate LVOT SV.
Source: Journal of Cardiothoracic and Vascular Anesthesia - May 16, 2023 Category: Anesthesiology Authors: Brian Cowie, Leah Wright, Ben Costello, Kristel Janssens, Erin Howden, Darragh Flannery, Steve Foulkes, Roman Kluger, Andre La Gerche Tags: Original Article Source Type: research
ACC 2019: Medtronic, Edwards low-risk TAVR trial data could pave way to new indications
Results from trials of both Medtronic‘s (NYSE:MDT) and Edwards Lifesciences‘ (NYSE:EW) transcatheter aortic valve replacement systems exploring their use in low-risk patients indicated that the devices were as safe as open surgery, paving the way for possible new indications for TAVR technology.
Data from the trials were presented over the weekend at the American College of Cardiology 68th Annual Scientific Session 2019 in New Orleans and simultaneously published in the New England Journal of Medicine.
Currently, TAVR devices are only approved by the FDA for treating severe aortic valve stenosis in patients at inte...
Source: Mass Device - March 18, 2019 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Clinical Trials Featured Replacement Heart Valves Edwards Lifesciences Medtronic Source Type: news
Post-Surgical Cognitive Outcomes (S62.001)
CONCLUSIONS:Patients who undergo AVR demonstrate persistent cognitive decline characterized by diminished learning on tests of memory and language and related to perioperative clinical stroke. These findings underscore the importance of ischemic neurologic complications of surgery and the need for improved stroke prevention and treatment strategies.Study Supported by: R01HL084375 to T.F.F.Disclosure: Dr. Giovannetti has nothing to disclose. Dr. Fanning has nothing to disclose. Dr. Ratcliffe has nothing to disclose. Dr. Price has nothing to disclose. Dr. Messe has received personal compensation for activities with GlaxoSmit...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Giovannetti, T., Fanning, M., Ratcliffe, S., Price, C., Messe, S., Selnes, O., Acker, M., Floyd, T., Szeto, W., Bavaria, J. Tags: Cerebrovascular Disease and Interventional Neurology: Cognitive and Behavioral Source Type: research
Edwards Lifesciences touts intermediate-risk data for Sapien devices | ACC 2016
Data from a large trial of the Sapien line of replacement heart valves made by Edwards Lifesciences (NYSE:EW) are slated to be used to back bids for expanded indications in intermediate-risk patients.
Presented over the weekend at the American College of Cardiology’s annual meeting in Chicago, results from the Partner II trial involving the Sapien XT and Sapien 3 transcatheter aortic valve replacements compared the TAVR treatments with traditional open surgery in the intermediate-risk cohort (both of the Edwards valves are already approved in the U.S. for high-risk patients).
Sapien XT non-inferior to surgery at 2...
Source: Mass Device - April 4, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Cardiovascular Clinical Trials Replacement Heart Valves American College of Cardiology Conference (ACC) Edwards Lifesciences Source Type: news
Cerebral Ischemic Events Associated with Transcatheter Aortic Valve Replacement (TAVR): A Systematic Review (P2.275)
Conclusions: In comparison to SAVR, existing data indicates marginally higher incidence of stroke with TAVR during the peri-procedural period. Inconsistencies were noted in long term clinical outcomes including stroke/TIA incidence with TAVR. Future research should focus on patient selection, improvement in valve technology and procedural techniques to minimize the observed risk.Disclosure: Dr. Herial has nothing to disclose. Dr. Mohammad has nothing to disclose. Dr. Morad has nothing to disclose. Dr. Qureshi has nothing to disclose. Dr. Qureshi has nothing to disclose.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Herial, N., Mohammad, N., Morad, C., Qureshi, M., Qureshi, A. Tags: Cerebrovascular Disease and Interventional Neurology: PFO and Other Cardiac Disease Source Type: research
The Incidence and Predictors of Early- and Mid-Term Clinically Relevant Neurological Events After Transcatheter Aortic Valve Replacement in Real-World Patients
ConclusionsTreatment of high-risk patients with aortic stenosis using a self-expandable system was associated with a low stroke rate at short- and long-term follow-up. Multivariable predictors of clinically relevant neurological events differed on the basis of the timing after TAVR. (CoreValve Advance International Post Market Study; NCT01074658)
Source: Journal of the American College of Cardiology - July 13, 2015 Category: Cardiology Source Type: research
Study of Boston Scientific ’s Lotus, Medtronic’s CoreValve shows similar outcomes at 2 years
Two-year results from a head-to-head study comparing transcatheter aortic heart valve replacement devices from both Boston Scientific (NYSE:BSX) and Medtronic (NYSE:MDT) indicated similar outcomes for the competing products.
The study, published recently in the journal JAMA Cardiology, compared Marlborough, Mass.-based Boston Scientific’s Lotus valve to Fridley, Minn.-based Medtronic’s CoreValve system.
Investigators in the study compared outcomes for 912 patients with high or extreme risk and severe, symptomatic aortic stenosis after treatment with one of the two devices.
Patients, treated between September 22, 2014...
Source: Mass Device - February 28, 2019 Category: Medical Devices Authors: Fink Densford Tags: Cardiovascular Clinical Trials Featured Replacement Heart Valves Boston Scientific Medtronic Source Type: news
1-Year Clinical Outcomes in Women After Transcatheter Aortic Valve Replacement: Results From the First WIN-TAVI Registry
Conclusions
Intermediate to high-risk women enrolled in this first ever all-women contemporary TAVR registry experienced a 1-year VARC-2 composite efficacy endpoint of 16.5%, with a low incidence of 1-year mortality and stroke. Prior revascularization and EuroSCORE I were independent predictors of the VARC-2 efficacy endpoint, whereas EuroSCORE I, baseline atrial fibrillation, and prior percutaneous coronary intervention were independent predictors of the 1-year death or stroke.
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - January 1, 2018 Category: Cardiology Authors: Chieffo, A., Petronio, A. S., Mehilli, J., Chandrasekhar, J., Sartori, S., Lefevre, T., Presbitero, P., Capranzano, P., Tchetche, D., Iadanza, A., Sardella, G., Van Mieghem, N. M., Meliga, E., Dumonteil, N., Fraccaro, C., Trabattoni, D., Mikhail, G., Shar Tags: Focus on Cardiovascular Outcomes Among Women Source Type: research
MassDevice EuroPCR 2018 Roundup
Valve Tech Roundup – Transcath heart valves getting safer, seeing expanded use
Abbott touts initial data from Portico TAVR study
Abbott (NYSE:ABT) today released 30-day data from a study of its Portico transcatheter aortic valve replacement, touting excellent clinical outcomes and low rates of death, disabling stroke and paravalvular leak.
The real-world, multicenter, prospective, single-arm Portico I study aimed to explore the safety and efficacy of the Portico valve with independent adjudication of clinical events and independent echocardiography core-lab analysis.
Investigators in the study will follow pa...
Source: Mass Device - May 22, 2018 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Clinical Trials Replacement Heart Valves Abbott Edwards Lifesciences Esaote Source Type: news
Cerebral Embolism A Silent Iatrogenic Complication of TAVR That Needs Voiced Consideration ∗
Transcatheter aortic valve replacement (TAVR) has rapidly and definitely changed the way patients with aortic stenosis are treated. Both the number of procedures and the indications have increased worldwide, allowing the inoperable patient to be treated, the high risk patient to be treated less invasively, and the intermediate risk patient to have the choice of an alternative to surgery (1–4). Clinical stroke or transient ischemic attack is not uncommon after aortic stenosis treatment, ranging in the randomized studies from 5% to 6% at 30 days to 8% to 10% at 1 year —one-half of them being major/disabling strokes (Tabl...
Source: Journal of the American College of Cardiology - August 2, 2016 Category: Cardiology Source Type: research
Cardiopulmonary Exercise Testing in Aortic Stenosis.
CONCLUSIONS: In this group of patients, where clinical assessment is difficult and conventional exercise testing is regarded as less useful, CPX showed high feasibility and reproducibility. CPX therefore has potential as a useful tool for serial monitoring. In general, the stroke volume increased during exercise, including in patients with severe aortic stenosis or decreased resting stroke volume. CPX gives information on hemodynamics and the physiologic components that determine decreased pVO2. CPX seems useful to identify 1) patients with a low risk of cardiac death and low risk of progression to symptoms from the aortic...
Source: Danish Medical Journal - May 31, 2017 Category: General Medicine Tags: Dan Med J Source Type: research
Routine cerebral embolic protection in transcatheter aortic valve implantation: rationale and design of the randomised British Heart Foundation PROTECT-TAVI trial
EuroIntervention. 2023 Jan 26:EIJ-D-22-00713. doi: 10.4244/EIJ-D-22-00713. Online ahead of print.ABSTRACTTranscatheter aortic valve implantation (TAVI) is an established treatment for aortic stenosis. Cerebral embolic protection (CEP) devices may impact periprocedural stroke by capturing debris destined for the brain. However, there is a lack of high-quality randomised trial evidence supporting the use of CEP during TAVI. The British Heart Foundation (BHF) PROTECT-TAVI trial will address whether the routine use of CEP reduces the incidence of stroke in patients undergoing TAVI. BHF PROTECT-TAVI is a prospective, open-label...
Source: EuroIntervention - January 27, 2023 Category: Cardiovascular & Thoracic Surgery Authors: Rajesh K Kharbanda Alexander David Perkins James Kennedy Adrian P Banning Andreas Baumbach Daniel J Blackman Matthew Dodd Richard Evans David Hildick-Smith Zahra Jamal Peter Ludman Stephen Palmer Rodney Stables Tim Clayton Source Type: research
